Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $11.50.
A number of brokerages recently weighed in on KPTI. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 21st. HC Wainwright cut Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research report on Friday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. Piper Sandler cut their price objective on shares of Karyopharm Therapeutics to $7.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Finally, Robert W. Baird cut shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Friday, July 31st.
View Our Latest Report on KPTI
Karyopharm Therapeutics Price Performance
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.21. The business had revenue of $35.07 million during the quarter, compared to the consensus estimate of $31.40 million. On average, analysts anticipate that Karyopharm Therapeutics will post -4.29 earnings per share for the current fiscal year.
Institutional Trading of Karyopharm Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LLC purchased a new position in shares of Karyopharm Therapeutics during the fourth quarter worth $74,000. Baird Financial Group Inc. purchased a new position in shares of Karyopharm Therapeutics during the 2nd quarter valued at about $45,000. Hsbc Holdings PLC purchased a new stake in shares of Karyopharm Therapeutics in the first quarter worth about $66,000. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics in the fourth quarter worth about $95,000. Finally, XTX Topco Ltd purchased a new position in Karyopharm Therapeutics during the second quarter valued at approximately $56,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.
About Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.
Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.
Featured Stories
- Five stocks we like better than Karyopharm Therapeutics
- These Outperforming Giants Are Boosting Dividends in 2026, With Yields of Up to 6.6%
- Why Analysts Are Bullish on a Stock That’s Down 20%
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
